Study Gives Hope of Altering Genes to Repel H.I.V.
By Denise Grady,
The New York Times
| 03. 05. 2014
The idea of genetically altering people’s cells to make them resist the virus that causes AIDS may seem like a pipe dream, but a new report suggests it can be done.
The research involves the first use in humans of “gene editing,” a treatment that zeros in on a particular gene and disables it.
In 12 people infected with H.I.V., scientists used the technique to get rid of a protein on the patients’ immune cells that the virus must latch onto to invade the cells. Cells were removed from the patients, treated and then dripped back into their bloodstreams through an intravenous line.
In theory, if enough cells could be engineered to repel the virus, patients might no longer need antiviral drugs, and might in effect be cured.
The experiment was a pilot study, meant to test safety, not efficacy. It found that immune cells could be altered, and that doing so did not harm patients. The gene editing also seemed to help fight the infection in some cases, but the findings are preliminary and researchers cautioned that widespread use...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...